Invention Grant
- Patent Title: Anti-PD-L1 antibody and use thereof
-
Application No.: US17046265Application Date: 2018-08-27
-
Publication No.: US11993655B2Publication Date: 2024-05-28
- Inventor: Bohua Li , Huajing Wang , Xiaowen He
- Applicant: Oricell Therapeutics Co., Ltd.
- Applicant Address: CN Shanghai
- Assignee: Oricell Therapeutics Co., Ltd.
- Current Assignee: Oricell Therapeutics Co., Ltd.
- Current Assignee Address: CN Shanghai
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: CN 1810309302.5 2018.04.09
- International Application: PCT/CN2018/102584 2018.08.27
- International Announcement: WO2019/196309A 2019.10.17
- Date entered country: 2020-10-08
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K31/713 ; A61P35/00 ; C12N5/10 ; C12N15/63 ; A61K39/00

Abstract:
An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.
Public/Granted literature
- US20210380698A1 ANTI-PD-L1 ANTIBODY AND USE THEREOF Public/Granted day:2021-12-09
Information query